



Budget October 2022-23

This information is accurate as of 25 October 2022.

Pharmaceutical Benefits Scheme - new and amended listings

This measure lists new medicines on the Pharmaceutical Benefits Scheme (PBS) and expands access to others.

This will provide for the better treatment and improved health of Australians.

These changes are based on recommendations to the Australian Government from the independent Pharmaceutical Benefits Advisory Committee.

The PBS provides subsidised access to medicines to:

- Australian residents
- overseas visitors from countries under Reciprocal Health Care Agreements.

The PBS is managed by the Department of Health and Aged Care and administered by Services Australia.

You can learn more about [the PBS](#) on its website.

New and amended listings from 1 July 2022

- Larotrectinib (Vitrakvi®) for the treatment of solid tumors harbouring neurotrophic receptor tyrosine kinase gene fusions.
- Zanubrutinib (Brukinsa ®) for the treatment of Waldenström macroglobulinemia.
- Amifampridine (Ruzurgi ®) for the treatment of Lambert-Eaton myasthenic syndrome.
- Molnupiravir (Lagevrio®) and nirmatrelvir and ritonavir (Paxlovid®) for the treatment of COVID-19 infection.

New and amended listings from 1 August 2022

- Nusinersen (Spinraza®) for the treatment of adult patients with spinal muscular atrophy.
- Infliximab (Remsima SC®) for the treatment of ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, refractory fistulising Crohn's disease.

New and amended listings from 1 September 2022

- Dapagliflozin (Forxiga®) for the treatment of chronic kidney disease.
- Nusinersen (Spinraza®) for the treatment of spinal muscular atrophy (SMA) to include all paediatric patients with Type III SMA, including Type IIIb SMA.
- Niraparib (Zejula®) for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
- Gilteritinib (Xospata®) for the treatment of acute myeloid leukaemia.

New and amended listings from 1 October 2022

- Nivolumab (Opdivo®) for the treatment of advanced or metastatic gastro-oesophageal cancers.
- Decitabine with cedazuridine (Inqovi®) for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukaemia.
- Somatrogon (Ngenla®) for the treatment of short stature associated with biochemical growth hormone deficiency and short stature and slow growth in patients who do not have a mature skeleton.
- Mecasermin (Increlex®) for the long term treatment of growth failure in children and adolescents from 2 to 18 years with severe primary insulin-like growth factor 1 deficiency.
- Avelumab (Bavencio®) for the treatment of locally advanced or metastatic urothelial carcinoma.
- Pembrolizumab (Keytruda®) for the treatment of squamous cell carcinoma of the head and neck.

New and amended listings from 1 November 2022

- Cemiplimab (Libtayo®) for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.

Services Australia has been allocated \$0.8 million in 2022-23 and \$1.4 million over 4 years for the implementation of this measure.

This measure is not subject to the passage of legislation.

Who does this measure affect?

This affects Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

When will this start and finish?

The new and amended PBS listings are effective from the dates stated above and are ongoing.